Page last updated: 2024-11-02

pioglitazone and Nephrotic Syndrome

pioglitazone has been researched along with Nephrotic Syndrome in 5 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Nephrotic Syndrome: A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.

Research Excerpts

ExcerptRelevanceReference
"While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS."8.31Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023)
" We found that puromycin aminonucleoside-induced proteinuria in rats was significantly reduced by both high-dose glucocorticoids (79%) and pioglitazone (61%), but not low-dose glucocorticoids (25%)."7.83Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome. ( Agrawal, S; Benndorf, R; Chanley, MA; Guess, AJ; Hidalgo, G; Kitao, T; Nie, X; Smoyer, WE; Westbrook, D, 2016)
"Thrombosis is a potentially life-threatening nephrotic syndrome (NS) complication."5.56Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors. ( Agrawal, S; Chanley, MA; Kerlin, BA; Kino, J; Smoyer, WE; Waller, AP; Wolfgang, KJ, 2020)
" Pioglitazone, a PPAR-γ agonist with a protective action on podocytes, was reported in a few cases as helpful in reducing proteinuria when combined with steroids."4.84Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy. ( Balestra, E; Barbi, E; Ceconi, V; Conversano, E; Di Maso, V; Pennesi, M, 2024)
"While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS."4.31Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023)
" We found that puromycin aminonucleoside-induced proteinuria in rats was significantly reduced by both high-dose glucocorticoids (79%) and pioglitazone (61%), but not low-dose glucocorticoids (25%)."3.83Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome. ( Agrawal, S; Benndorf, R; Chanley, MA; Guess, AJ; Hidalgo, G; Kitao, T; Nie, X; Smoyer, WE; Westbrook, D, 2016)
"Acute podocyte injury and nephrotic syndrome were induced by puromycin aminonucleoside (PAN) injection in rats."3.78Protective effects of PPARγ agonist in acute nephrotic syndrome. ( Fogo, AB; Kon, V; Ma, LJ; Najafian, B; Potthoff, SA; Yang, HC; Zuo, Y, 2012)
"Thrombosis is a potentially life-threatening nephrotic syndrome (NS) complication."1.56Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors. ( Agrawal, S; Chanley, MA; Kerlin, BA; Kino, J; Smoyer, WE; Waller, AP; Wolfgang, KJ, 2020)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (40.00)24.3611
2020's3 (60.00)2.80

Authors

AuthorsStudies
Hunley, TE1
Hidalgo, G2
Ng, KH1
Shirai, Y1
Miura, K1
Beng, HM1
Wu, Q1
Hattori, M1
Smoyer, WE3
Balestra, E1
Barbi, E1
Ceconi, V1
Di Maso, V1
Conversano, E1
Pennesi, M1
Waller, AP1
Agrawal, S2
Wolfgang, KJ1
Kino, J1
Chanley, MA2
Kerlin, BA1
Westbrook, D1
Nie, X1
Kitao, T1
Guess, AJ1
Benndorf, R1
Zuo, Y1
Yang, HC1
Potthoff, SA1
Najafian, B1
Kon, V1
Ma, LJ1
Fogo, AB1

Other Studies

5 other studies available for pioglitazone and Nephrotic Syndrome

ArticleYear
Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome.
    Pediatric nephrology (Berlin, Germany), 2023, Volume: 38, Issue:4

    Topics: Child; Glomerulosclerosis, Focal Segmental; Humans; Nephrotic Syndrome; Pioglitazone; Proteinuria; S

2023
Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy.
    Pediatric nephrology (Berlin, Germany), 2024, Volume: 39, Issue:1

    Topics: Adolescent; Female; Humans; Immunosuppressive Agents; Mycophenolic Acid; Nephrotic Syndrome; Peroxis

2024
Nephrotic syndrome-associated hypercoagulopathy is alleviated by both pioglitazone and glucocorticoid which target two different nuclear receptors.
    Physiological reports, 2020, Volume: 8, Issue:15

    Topics: Animals; Blood Coagulation; Child; Female; Glucocorticoids; Humans; Male; Nephrotic Syndrome; Piogli

2020
Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome.
    Scientific reports, 2016, 05-04, Volume: 6

    Topics: Albuminuria; Animals; Creatinine; Cyclooxygenase 2; Drug Therapy, Combination; Glucocorticoids; Kidn

2016
Protective effects of PPARγ agonist in acute nephrotic syndrome.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2012, Volume: 27, Issue:1

    Topics: Actinin; Acute Disease; Animals; Antibiotics, Antineoplastic; Aquaporin 2; Blotting, Western; Cells,

2012